The FDA peptide vote, explained: what actually happened

What PCAC actually voted on

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate several peptides for possible addition to the Section 503A bulk drug substances list — the list of ingredients a licensed pharmacy is permitted to compound for a specific patient under a prescription.

The committee voted to recommend BPC-157 for the list by a margin of 8-6-1, and recommended KPV and TB-500 by the same 8-6-1 margin. It also recommended MOTS-c — a mitochondrial-derived peptide that is the only weight-loss-adjacent substance in the group — 7-5, on a smaller panel tally than the 8-6-1 votes (a two-vote margin in both cases). The next day, July 24, the committee recommended two more — Semax (8-5) and Epitalon (7-5-1) — and, in its only rejection of the meeting, voted against Emideltide (also called DSIP) by 6-7-1. Across the two days the FDA evaluated seven peptides in total, and the committee recommended six of them.

The single most important fact about this meeting is a structural one: PCAC is an advisory committee. Its recommendations are non-binding — the FDA is not required to adopt them. And on the six it recommended, the committee voted against the recommendation of the FDA's own career staff scientists, who had recommended against listing all seven and raised concerns about the thin or absent human evidence for these peptides; the only vote that agreed with staff was the Emideltide (DSIP) rejection. A recommendation from this committee is the beginning of a long regulatory process, not the end of one. The full, sourced breakdown of every peptide and its status is in our Peptide Compounding Status Index.

• BPC-157 — recommended for the 503A bulks list, 8-6-1 (advisory recommendation, against FDA staff).
• KPV and TB-500 — recommended by the same 8-6-1 margin (advisory recommendation, against FDA staff).
• MOTS-c — the only weight-loss-adjacent peptide in the set; recommended 7-5, on a smaller panel tally than the 8-6-1 votes (a two-vote margin in both cases; advisory recommendation, against FDA staff).
• July 24: Semax (8-5) and Epitalon (7-5-1) were also recommended, both against FDA staff; Emideltide (DSIP) was rejected 6-7-1 — the committee's only rejection of the meeting.

Why "approved" is the wrong word (and who says so)

Headlines that read "FDA approves peptides" get it wrong on two counts.

First, a PCAC recommendation is not FDA approval. Approval is a specific regulatory status — the outcome of a completed new-drug review in which the FDA evaluates a manufacturer's safety and effectiveness data. None of these peptides has that. What happened on July 23 is that an advisory committee suggested the FDA add certain ingredients to a compounding list. Those are different things at different ends of the regulatory system.

Second, even if the FDA eventually finalizes the addition, being on the 503A bulks list would only mean a pharmacy may compound the substance for an individual patient under a prescription. It would still not make the peptide an FDA-approved drug, and it would not make it therapeutically equivalent to anything.

And on the question of who says these peptides need more scrutiny: the FDA's own staff scientists did. They recommended against listing, citing insufficient or absent human data. The advisory committee overrode them. So the accurate statement — today, and even in the scenario where the list is finalized — is that these peptides are not FDA-approved.

Is it legal to get these now?

No. None of these peptides is on the FDA's 503A bulks list today, and none has completed the rulemaking that would be required to get there.

That rulemaking is a defined, multi-step process: the FDA publishes a proposed rule, opens a public-comment period, weighs the comments, and then issues — or declines to issue — a final rule. Historically it has taken 12 to 24 months, and the agency can decline at the end of it. We are deliberately not attaching a specific date to any of this, because no one credibly can. It is fair to note that the current administration has signaled it wants faster and broader access to compounded therapies, and that enforcement discretion has bridged other compounding situations in the past — but a policy signal is not a rule, and it is not a date.

This is also not the first time these peptides have moved through the FDA's 503A nomination process. Earlier in 2026 the agency revised how several of them — BPC-157, Semax, and TB-500 among others — sat within that process; this July advisory vote is a further step in the same unfinished sequence, not its conclusion. For the fuller regulatory history of compounding and the 503A framework, see our companion explainer, Is compounded semaglutide or tirzepatide legal in 2026?

The practical bottom line: anyone telling you these peptides are legal to order today is describing something that has not happened.

What the science actually shows

The evidence base for these peptides is thin — thinner than for the compounded GLP-1 medications that licensed providers prescribe through Cora, and thin enough that the FDA's own scientists flagged it. Based on the FDA materials, here is what the human data looks like, peptide by peptide.

We are not making an efficacy claim about any of these substances, because the human trial evidence to support one does not exist in the sources we reviewed. Individual results vary. For the three substances taken up on July 24 — Emideltide (DSIP, evaluated for opioid withdrawal, chronic insomnia, and narcolepsy), Semax (cerebral ischemia, migraine, and trigeminal neuralgia), and Epitalon (insomnia) — the FDA flagged the same thin or absent human data. The committee recommended Semax and Epitalon and rejected Emideltide; none of that is an efficacy finding, and we make no efficacy claim about any of them.

• BPC-157: studied for tissue and gut repair, and reviewed by the FDA in the context of ulcerative colitis. Human data is limited — a single small, decades-old abstract; FDA staff cited insufficient human data.
• KPV: a fragment of alpha-MSH studied for anti-inflammatory effects. No human clinical trials were located; FDA staff cited the absence of human data.
• TB-500: a thymosin beta-4 fragment studied for recovery and healing. No human clinical studies were located; FDA staff cited the absence of human data. TB-500 is also prohibited under the World Anti-Doping Agency (WADA) code.
• MOTS-c: a mitochondrial-derived peptide discussed in metabolic and weight-adjacent contexts (the FDA evaluated it for obesity and osteoporosis). No human clinical data was located, and it is prohibited under the WADA code. It was recommended 7-5 on July 23, on a smaller panel tally than the 8-6-1 votes — a two-vote margin in both cases.

How to spot the hype

A headline like this is fuel for grey-market sellers. Here is how to separate honest information from the marketing that will follow — each of these is a claim to distrust.

• A product page that labels a peptide as "FDA approved." No peptide in this vote is FDA-approved, and a recommendation to add a substance to a compounding list is not approval.
• A site that tells you these are "legal to order today." None is on the FDA's 503A bulks list, and the rulemaking that could add them has not been completed.
• Language like "the same as a prescription drug," "clinically proven," or "backed by studies." For several of these peptides the human evidence is a single old abstract — or nothing at all.
• A specific launch date ("available in weeks"). No one can credibly promise a timeline; the rulemaking can take 12 to 24 months and can be declined.
• No named compounding pharmacy, no prescription, and no real provider evaluation — the exact pattern the FDA has repeatedly cited in warning letters to telehealth sellers.

What this means for you right now

If you are curious about peptides, the honest answer today is: not yet — and not from anyone claiming otherwise.

At Cora, licensed providers prescribe compounded semaglutide and compounded tirzepatide after a real clinical evaluation. Those medications are themselves not FDA-approved and are not therapeutically equivalent to branded products like Ozempic®, Wegovy®, Mounjaro®, or Zepbound® (registered trademarks of their respective owners); they are compounded by two named US-licensed 503A pharmacies — Hallandale Pharmacy (PCAB-accredited) and VialsRx. Cora does not sell, prescribe, or compound the peptides in this vote, and will not offer any peptide therapy unless and until there is a compliant, legal pathway and a licensed provider decides it is appropriate for a given patient.

If you want honest updates as this develops — no hype, no sales pitch — you can join the list on our peptides page, and follow the status in our open Peptide Compounding Status Index. We would rather tell you accurately that something is not available than sell you something that is not ready.

FAQ: the FDA peptide vote

Did the FDA approve BPC-157 (or any peptide) on July 23, 2026? No. An FDA advisory committee (PCAC) voted to recommend adding some peptides, including BPC-157, to the list of substances pharmacies may compound under Section 503A. That is a non-binding recommendation, not FDA approval — and the committee voted against the recommendation of the FDA's own staff scientists. These peptides are not FDA-approved.

Is it legal to buy these peptides right now? No. None is on the FDA's 503A bulks list, and the rulemaking that could add them has not happened. Anyone selling them as legal to order today is making a false claim.

When will peptides be available through a legitimate provider? There is no reliable date. Adding a substance to the 503A bulks list requires a full FDA rulemaking that has historically taken 12 to 24 months and can be declined. We will not promise a timeline, and you should be skeptical of anyone who does.

What about the peptides evaluated on July 24? On July 24, 2026, PCAC recommended two of them — Semax (8-5) and Epitalon (7-5-1) — and rejected the third, Emideltide (DSIP), by 6-7-1, its only rejection of the meeting. That brings the two-day total to six of seven peptides recommended. All of these are advisory recommendations, not FDA approval; the meeting evaluated seven peptides in total and there is no additional session on the FDA's meeting notice.

Does Cora sell peptides? No. Cora does not sell, prescribe, or compound peptides. Licensed providers at Wasef Health, PC make all prescribing decisions, and any compounded medication Cora offers is prepared by Hallandale Pharmacy or VialsRx, both US-licensed 503A pharmacies. If a compliant pathway for peptide therapy opens, we will share honest updates first.

Sources

This article describes the July 23-24, 2026 PCAC advisory vote and the surrounding regulatory framework, updated July 25, 2026 with the confirmed two-day outcomes (six of seven peptides recommended; Emideltide/DSIP rejected). It is general information, not medical or legal advice. A PCAC recommendation is non-binding and is not FDA approval; regulations, meeting outcomes, and enforcement priorities change — verify current status directly with the FDA.

• FDA — Pharmacy Compounding Advisory Committee (PCAC). fda.gov
• FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. fda.gov
• FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (agenda and uses evaluated). fda.gov
• Reuters — FDA advisers back first four of seven unapproved peptides under review for looser rules (July 23, 2026; documents the 8-6-1 and 7-5 vote margins). reuters.com
• RAPS — FDA advisory committee backs two more peptides, rejects one for compounding list (July 24, 2026; documents the Semax 8-5, Epitalon 7-5-1, and Emideltide 6-7-1 votes). raps.org
• Cora Health — Is compounded semaglutide or tirzepatide legal in 2026? (companion regulatory explainer). trycora.io
• Cora Health — Peptide Compounding Status Index (the full sourced dataset, CC-BY-4.0). trycora.io